Avenue Therapeutics, Inc. (ATXI): Price and Financial Metrics
GET POWR RATINGS... FREE!
ATXI Stock Price Chart Interactive Chart >
ATXI Price/Volume Stats
| Current price | $0.25 | 52-week high | $2.69 |
| Prev. close | $0.27 | 52-week low | $0.20 |
| Day low | $0.25 | Volume | 217,900 |
| Day high | $0.28 | Avg. volume | 2,684,269 |
| 50-day MA | $0.31 | Dividend yield | N/A |
| 200-day MA | $0.82 | Market Cap | 5.48M |
Avenue Therapeutics, Inc. (ATXI) Company Bio
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. Its product candidate is IV Tramadol for the treatment of post-operative pain. The company was founded in 2015 and is based in New York, New York.
Latest ATXI News From Around the Web
Below are the latest news stories about Avenue Therapeutics Inc that investors may wish to consider to help them evaluate ATXI as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayGood morning, investors! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWelcome back, trader! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayRise and shine, trader! |
FDA's AdComm Says Avenue Therapeutics Submitted Insufficient Data On IV TramadolAvenue Therapeutics Inc (NASDAQ: ATXI) announced the outcome of the FDA meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee on IV tramadol. The Advisory Committee had to vote on "has the Applicant submitted adequate information to support the position that the benefits of their product outweigh the risks for the management of acute pain severe enough to require an opioid analgesic in an inpatient setting?" The result |
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV TramadolNEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the outcome of the U.S. Food and Drug Administration (“FDA”) joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee on IV tramadol. In the final part of the public meeting, the Advisory Committee voted yes or no on |
ATXI Price Returns
| 1-mo | -13.79% |
| 3-mo | -46.04% |
| 6-mo | -73.12% |
| 1-year | -90.12% |
| 3-year | -95.95% |
| 5-year | -96.88% |
| YTD | -72.47% |
| 2021 | -84.74% |
| 2020 | -38.02% |
| 2019 | 77.78% |
| 2018 | 49.17% |
| 2017 | N/A |
Loading social stream, please wait...